Regeneron Pharmaceuticals shares climbed 13.33% to $927.89 as of 11:17 UTC on November 1, according to delayed pricing data from Financial Modeling Prep, marking a multi-month high for the biotech company after a third-quarter earnings report that beat expectations. The stock had already jumped as it traded at $929.69 around 9:45 a.m. ET on October 30, according to 24/7 Wall Street, with the move driven by strength in two of the company's key franchises.
The earnings beat centers on Regeneron's third-quarter 2026 results, which showed revenue growth of 36% year over year to $5.1 billion, according to commentary from the company's earnings call reported by MarketBeat. That growth was powered in significant part by royalty income tied to Dupixent, the anti-inflammatory drug Regeneron developed in partnership with Sanofi, as well as continued sales momentum for Eylea HD, the company's higher-dose treatment for retinal diseases.
For investors, the magnitude of the move stands out both in absolute terms and relative to the broader market. Regeneron's gain came on a day when much of the technology and healthcare sectors were under pressure. Chipmakers were hit particularly hard, with Intel down 28.6%, Qualcomm down 11.1%, Advanced Micro Devices down 10.9% and Applied Materials down 7.5%. Oracle fell 6.4% and Palantir Technologies dropped 6.3%. Within healthcare, Stryker was off 6.4%, underscoring that Regeneron's rally was not simply a function of sector-wide tailwinds but appeared tied to company-specific news.
The divergence from peers in its own industry was notable as well. Coverage from the day's trading session noted that Moderna slid 2% while Merck and Pfizer posted more modest moves, suggesting the Dupixent royalty growth and Eylea HD performance were being read by the market as a distinct catalyst for Regeneron rather than a broad rerating of pharmaceutical stocks.
Regeneron's performance over longer horizons has also strengthened. Beyond the single-day move, the stock has gained 15.26% over the past week, 26.21% over the past month and 19.53% year to date, with a 42.36% increase over the trailing twelve months, according to the pricing data. That pattern indicates the October 30 earnings reaction built on a stock that had already been trending higher heading into the print.
Background on the company's business model helps explain why the Dupixent royalty stream matters so much to its financial results. Dupixent is marketed and sold primarily by Sanofi, with Regeneron entitled to royalty payments on net sales under their longstanding collaboration agreement. As Dupixent sales have expanded across its approved indications, those royalties have become an increasingly important contributor to Regeneron's top line, supplementing direct product revenue from treatments the company sells on its own, including Eylea HD.
The broader market backdrop on the day of Regeneron's surge was shaped by weakness concentrated in technology and semiconductor names, a pullback that overshadowed gains elsewhere in healthcare and left Regeneron as a standout performer. Cryptocurrency markets traded in a narrower range by comparison, with bitcoin near $77,969 and ether near $2,269.82, both posting modest gains, while the crypto sector worked through fallout from a reported hack at Binance that drew attention away from equities for some traders.
Looking ahead, investors and analysts will likely focus on whether Dupixent's royalty growth trajectory and Eylea HD's sales momentum can be sustained in coming quarters, as those two franchises were cited as the primary drivers behind the earnings beat. Attention will also turn to how Regeneron's results compare with upcoming reports from other large pharmaceutical and biotech companies, and whether the stock's sharp rally proves durable once the initial earnings reaction fades. As with any single-day move of this magnitude, market participants will be watching subsequent trading sessions to see whether the gain holds or partially reverses as the broader market digests a volatile week for technology and healthcare shares alike.